The Scottish Government’s newly unveiled Programme for Government includes several promising commitments for rural communities, though Scottish Land & Estates (SLE) has called for a more consistent ...

SLE is a complex, heterogeneous, inflammatory, chronic autoimmune disease in which the body's immune system attacks its own tissues, including skin, joints, and kidneys. Skin is the second most ...

Super League Enterprise (SLE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $3.47 per share a year ago.

The SLE Rodeo is coming to Montgomery. The rodeo officially kicks off with a parade through downtown Montgomery at Noon on Friday. Activities will continue all weekend long such as team roping ...

Pharmaceutical Executive: What preclinical or early clinical data supports the concept of an 'immune reset' in SLE/LN, and what are you tracking in trials to assess the potential for achieving this?

MONTGOMERY, Ala. (WSFA) - The 68th annual SLE rodeo is coming back to town. Starting off the festivities, March 7 through 8 will be SLE’s inaugural Alabama select horse sale at the Teague arena.

In addition, genes with unknown roles in SLE pathophysiology have been identified ... Toll-like receptor (TLR) function and type I interferon production; and immune signal transduction in lymphocytes.

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Petrolheads often spend hours on end poring over the latest models from their favorite manufacturers. As much fun as it is salivating over their specs and considering the virtues of different ...

There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and SLE pathophysiology, and two phase I clinical studies of E6742, a small molecular selective dual antagonist of ...